- Home
- UPXI vs ONVO Comparison
UPXI vs ONVO Comparison
Compare UPXI & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- ONVO
- Stock Information
- Founded
- UPXI 2018
- ONVO 2007
- Country
- UPXI United States
- ONVO United States
- Employees
- UPXI N/A
- ONVO N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UPXI Health Care
- ONVO Health Care
- Exchange
- UPXI Nasdaq
- ONVO Nasdaq
- Market Cap
- UPXI 3.6M
- ONVO 3.0M
- IPO Year
- UPXI 2021
- ONVO N/A
- Fundamental
- Price
- UPXI $15.51
- ONVO $1.87
- Analyst Decision
- UPXI
- ONVO
- Analyst Count
- UPXI 0
- ONVO 0
- Target Price
- UPXI N/A
- ONVO N/A
- AVG Volume (30 Days)
- UPXI 6.5M
- ONVO 347.1K
- Earning Date
- UPXI 05-07-2025
- ONVO 05-30-2025
- Dividend Yield
- UPXI N/A
- ONVO N/A
- EPS Growth
- UPXI N/A
- ONVO N/A
- EPS
- UPXI N/A
- ONVO N/A
- Revenue
- UPXI $18,625,089.00
- ONVO $122,000.00
- Revenue This Year
- UPXI $299.03
- ONVO $59.08
- Revenue Next Year
- UPXI N/A
- ONVO $18.24
- P/E Ratio
- UPXI N/A
- ONVO N/A
- Revenue Growth
- UPXI 4.75
- ONVO N/A
- 52 Week Low
- UPXI $1.90
- ONVO $1.56
- 52 Week High
- UPXI $22.53
- ONVO $21.96
- Technical
- Relative Strength Index (RSI)
- UPXI 88.68
- ONVO 37.84
- Support Level
- UPXI $9.81
- ONVO $1.56
- Resistance Level
- UPXI $22.00
- ONVO $1.78
- Average True Range (ATR)
- UPXI 2.41
- ONVO 0.24
- MACD
- UPXI 1.41
- ONVO 0.13
- Stochastic Oscillator
- UPXI 65.96
- ONVO 43.06
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.